Phaseline

Targets › PDCD274

PDCD274: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: the race on PDCD274, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SparX Biotech(Jiangsu) Co., Ltd.SPX-303
Bispecific antibody targeting LILRB2 and PD-L1
LILRB2, PDCD274Phase 1Solid TumorSep 2027

Conditions

Solid Tumor (1)

Modalities

antibody (1)

Companies

SparX Biotech(Jiangsu) Co., Ltd. (1)

Related targets

LILRB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.